Alzheon – Framingham Source

Alzheon Appoints Former IVAX President as Vice Chair of Board

August 9, 2018August 10, 2018 Framingham Source Editor Susan Petroni 0 Comments Alzheon, biopharmaceutical company, Board of Directors, Inc., IVAX, Neil Flanzraich

FRAMINGHAM – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurological

Business

Framingham-Based Company’s Scientists Discover Key Driver of Alzheimer’s Disease

August 6, 2018August 18, 2018 Framingham Source Editor Susan Petroni 0 Comments Alzheimer's Disease, Alzheon

FRAMINGHAM – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurodegenerative

Business Health

Framingham Company Developing Alzheimer’s Disease Treatments Launches Initial Public Offering

April 2, 2018April 4, 2018 Framingham Source Editor Susan Petroni 0 Comments Alzheimer's disease treatments, Alzheon, initial public offering, NASDAQ, Stock

FRAMINGHAM – Alzheon, Inc. announced today, April 2, it has launched the roadshow for the initial public offering of its common stock.

Business

FDA Fast Tracks Framingham Company’s Drug To Treat Alzheimer’s Disease

October 26, 2017October 26, 2017 Framingham Source Editor Susan Petroni 0 Comments ALZ-801, Alzheon, Food and Drug Administration (FDA)

FRAMINGHAM – Alzheon, Inc., a clinical stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and

Business

Framingham-Based Alzheon Appoints Chief Business Officer

February 28, 2017March 3, 2017 Framingham Source Editor Susan Petroni 0 Comments Alzheon, Neil Flanzraich

FRAMINGHAM – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and